grant
Targeting Evasion Factors: Discovery of novel antibodies for durable suppression of HSV reactivation
NIHUS FederalResearch GrantFY20267S Gamma GlobulinAcicloftalAclovirAcycloguanosineAcyclovirAffectAnti-viral AgentsAntibodiesAutomobile DrivingBenchmarkingBest Practice AnalysisBindingBlindnessBrain InflammationC3bCargosilCell BodyCellsChicken PoxChickenpoxChickenpox VirusChronicClinicalClinical Treatment MoabCold SoreComplement 3bComplement ActivationComplement C3bComplexComplex thinkingCritical ThinkingDataDevelopmentDevelopment and ResearchDiseaseDisorderEffectivenessEncephalitisEngineeringEpidemiologyEvaluative ThinkingExhibitsFab domainFamily memberFc domainFever BlisterFrequenciesGenital OrgansGenitaliaGlycoproteinsGoalsHHV-2HHV-3HHV2HHV3HSVHSV glycoprotein CHSV type 1 glycoprotein gCHSV-1HSV-1 gC-1HSV-2HSV-I glycoprotein CHSV1HSV2Herpes LabialisHerpes Simplex Type 1Herpes Simplex VirusHerpes Simplex Virus 1Herpes Simplex Virus 2Herpes Simplex Virus Type 1Herpes Simplex Virus Type 2Herpes ZosterHerpes labialis VirusHerpes zoster VirusHerpes zoster diseaseHerpesviridaeHerpesvirus 1Herpesvirus 2 (alpha), HumanHerpesvirus Type 3Herpesvirus progenitalisHerpesvirus varicellaeHerpesvirusesHerpetic StomatitisHost DefenseHumanHuman (alpha) herpes virus 2Human Herpesvirus 2Human herpes simplex virus type 2IgGImmuneImmunesImmunoglobulin GIncidenceIndividualInfectionInfection preventionLabial Herpes SimplexLesionMediatingMiceMice MammalsModern ManMolecular InteractionMonoclonal AntibodiesMonoclonal Antibody TherapyMorbidityMurineMusNational Institutes of HealthNerve DegenerationNeuron DegenerationOcular Herpes zoster VirusOral Herpes SimplexPersonsPopulationPoviralPre-Clinical ModelPreclinical ModelsPrevent infectionPreventative vaccinePreventionPreventive vaccineProphylactic vaccineProteinsR & DR&DRecombinantsRecurrenceRecurrentResearchResistanceRiskRisk FactorsSeveritiesShinglesSimplexvirusSpecificityStrategic PlanningSurfaceTestingTherapeuticTimeTransmissionUnited States National Institutes of HealthVZ VirusVaccinesVaricellaVaricella-Zoster VirusViralViral ActivityViral AntibodiesViral DiseasesViral FunctionViral PathogenesisViral PhysiologyViral SheddingVirionViroraxVirusVirus DiseasesVirus ParticleVirus SheddingZonaZosterZoviraxanti-viral antibodyanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsantibody engineeringbenchmarkcomplement pathway regulationdevelopmentaldrivingdrug-sensitiveepidemiologicepidemiologicalglycoprotein Cguinea pig modelherpes febrilisherpes simplex iherpes simplex iiherpes simplex virus-1 glycoprotein Cherpes simplex-1herpes virusherpes zonahigh rewardhigh riskhuman alphaherpesvirus 2immune clearanceimmune eliminationimprovedin vivoinnovateinnovationinnovativeintraoral herpes simplex infectionintraoral hsv infectionlatency/reactivationlatent virus activationmAB-based therapymAb therapymAb-based therapeuticsmAbsmonoclonal Absnerve cell deathnerve cell lossneural degenerationneurodegenerationneurodegenerativeneurological degenerationneuron cell deathneuron cell lossneuron deathneuron lossneuronal cell deathneuronal cell lossneuronal deathneuronal degenerationneuronal lossnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoral HSVoral herpesoral mucosal herpespathogenpre-clinicalpreclinicalpreventpreventingreactivation from latencyresearch and developmentresistance strainresistantresistant strainresponseseropositivetherapeutic agent developmenttherapeutic developmenttherapeutic vaccinetransmission processtreatment vaccinesvaccine antibodiesvaccine for the treatmentvaccine for treatmentvaccine induced antibodiesvaccine platformvaccine-induced antibodiesviral infectionvirus infectionvirus pathogenesisvirus-induced diseasevision lossvisual loss
Description preview
ABSTRACT
Chronically-reactivating HSV is an underserved disease. Beyond lesions suffered by affected
individuals, reactivation results in risk of transmission to others, especially as subclinical reactivation occurs
with high frequency. Further, the isolation of ACV resistant strains, the inability of long-term ACV treatment to
fully control…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click